The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Melflufen in patients with refractory MM: updated analysis of HORIZON
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the updated analysis of the ongoing HORIZON study (NCT02963493) in patients with multiple myeloma (MM) refractory to pomalidomide and/or daratumumab, including a subgroup analysis of patients with triple-class refractory (no response or progression to at least one immunomodulatory imide drugs (IMiD), one proteasome inhibitor, and one anti-CD38 monoclonal antibody) and high-risk cytogenetics at baseline. Melflufen shows promising activity, including in subsets of patients with poor-risk features, including triple-class refractory and high-risk cytogenetics. Dr Mateos expects melflufen to be approved soon in order to be included in the treatment landscape of MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
